Lunger Fabian, Aeschbacher Pauline, Nett Philipp C, Peros Georgios
Department for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland.
Front Surg. 2022 Jul 15;9:918272. doi: 10.3389/fsurg.2022.918272. eCollection 2022.
Obesity (BMI ≥ 30 kg/m) with related comorbidities such as type 2 diabetes mellitus, cardiovascular disease, sleep apnea syndrome, and fatty liver disease is one of the most common preventable risk factors for cancer development worldwide. They are responsible for at least 40% of all newly diagnosed cancers, including colon, ovarian, uterine, breast, pancreatic, and esophageal cancer. Although various efforts are being made to reduce the incidence of obesity, its prevalence continues to spread in the Western world. Weight loss therapies such as lifestyle change, diets, drug therapies (GLP-1-receptor agonists) as well as bariatric and metabolic surgery are associated with an overall risk reduction of cancer. Therefore, these strategies should always be essential in therapeutical concepts in obese patients. This review discusses pre- and post-interventional aspects of bariatric and metabolic surgery and its potential benefit on cancer development in obese patients.
肥胖（体重指数≥30kg/m²）以及2型糖尿病、心血管疾病、睡眠呼吸暂停综合征和脂肪肝等相关合并症是全球范围内癌症发生最常见的可预防风险因素之一。它们导致了至少40%的新诊断癌症，包括结肠癌、卵巢癌、子宫癌、乳腺癌、胰腺癌和食管癌。尽管人们正在做出各种努力来降低肥胖的发生率，但其患病率在西方世界仍在持续上升。诸如生活方式改变、饮食、药物治疗（胰高血糖素样肽-1受体激动剂）以及减肥和代谢手术等减肥疗法与癌症总体风险降低相关。因此，这些策略在肥胖患者的治疗理念中应始终至关重要。本综述讨论了减肥和代谢手术的干预前后情况及其对肥胖患者癌症发生的潜在益处。
